About Us

Nebulabio is a premier biotechnology Contract Research Organization (CRO) specializing in advanced in vitro antibody discovery solutions. With over 15 years of dedicated experience in phage display technology, our platform has become a trusted partner for pharmaceutical companies, academic institutions, and biotechnology startups worldwide. Our core expertise focuses specifically on the scFv (single-chain variable fragment) format, offering integrated services from custom library construction through high-efficiency screening and lead optimization. Our team of molecular biologists, protein engineers, and bioinformaticians has successfully delivered thousands of functional scFv leads against targets ranging from soluble proteins to complex membrane receptors, accelerating research and therapeutic development programs globally.

☞Introduction to scFv Phage Display Technology

■ Scientific Foundation and Historical Development

The single-chain variable fragment (scFv) represents one of the most significant innovations in antibody engineering. An scFv consists of the variable heavy (VH) and variable light (VL) domains of an antibody, connected by a flexible peptide linker (typically 15-25 amino acids, often (Gly₄Ser)₃). This design preserves the antigen-binding capability of a full antibody within a compact, single-polypeptide chain of approximately 27 kDa.

The integration of scFv technology with phage display created a revolutionary antibody discovery platform. The foundational phage display technology was pioneered by Dr. George P. Smith in 1985, demonstrating that foreign peptides could be displayed on bacteriophage surfaces. This concept was then brilliantly adapted for antibody fragments by Sir Gregory P. Winter and colleagues in the early 1990s, who first displayed functional scFvs on phage. This breakthrough enabled the creation of vast in vitro antibody libraries independent of animal immunization. The profound impact of this work was recognized with the 2018 Nobel Prize in Chemistry, awarded jointly to Dr. Smith and Sir Winter (along with Frances H. Arnold).

■ Mechanistic Principle

In scFv phage display, the scFv gene is genetically fused to a gene encoding a bacteriophage coat protein (most commonly the minor coat protein pIII of the M13 filamentous phage). When the engineered phage infects E. coli, the scFv-pIII fusion protein is expressed and incorporated into newly assembled phage particles. Each phage particle displays the scFv on its surface while encapsulating the DNA that encodes it, creating a direct physical link between phenotype (binding function) and genotype (DNA sequence). This linkage enables the powerful in vitro selection process called biopanning, where a library of billions of scFv-displaying phages can be rapidly enriched for specific binders against any target.

☞scFv Library Construction & Screening Process: Core Methodology

Our platform is built on a robust, two-phase methodology that has been refined through years of practice and is supported by extensive scientific literature.

 Phase A: scFv Library Construction Process 

⒈Genetic Source Acquisition: Starting material is obtained based on library type:

• Naïve/Immune Libraries: RNA from B-cells (human PBMCs, immunized animal spleen) is reverse transcribed to cDNA.

• Synthetic Libraries: Designed V-gene segments are synthesized de novo.

⒉V-Gene Amplification: VH and VL genes are PCR-amplified using family-specific or degenerate primers.

⒊Assembly & Cloning: VH and VL pools are spliced together via SOE-PCR with an intervening linker sequence to form full scFv genes. This pool is then cloned into a phagemid vector upstream of the gene III sequence.

⒋Library Transformation: The ligated DNA is electroporated into E. coli to create the primary bacterial library, with diversities typically reaching 10⁹ - 10¹¹ individual clones.

⒌Phage Rescue & QC: Helper phage infection produces the scFv-displaying phage library, which undergoes quality control for size, insert rate, and diversity.

 Phase B: scFv Library Screening (Biopanning) Process 

⒈Antigen Immobilization: The target antigen is immobilized on a solid surface (plate, beads) or biotinylated for solution-phase capture.

⒉Selection Rounds (3-5 cycles): The phage library undergoes iterative rounds of:

• Binding to the target.

• Stringent Washing to remove non-binders.

• Elution of specific binders (via pH shift or competition).

• Amplification by infecting E. coli with eluted phage.

⒊Hit Identification: Individual clones from the final output are screened via monoclonal phage ELISA.

⒋Characterization: Positive clones are sequenced, and unique scFvs are expressed in soluble form for validation of binding, affinity (e.g., by BLI/SPR), and specificity.

Figure1.Workflow of scFv library generation and phage display affinity selection. 

☞Nebulabio Integrated Service Workflow

We offer a seamless, end-to-end service pipeline from initial concept to deliverable leads. Our process is designed for transparency, efficiency, and maximum project success.

 Step 1: Project Consultation & Design 

We begin with a deep dive into your target biology, project goals, and desired scFv properties. Together, we decide on the optimal strategy: library type (naïve, immune, or synthetic), screening approach, and success criteria.

Step 2: scFv Library Construction (If Required)

If a custom library is needed, our construction team executes the process described in Section 3, delivering a fully QC'd phage library with a comprehensive analysis report.

Step 3: High-Stringency Biopanning

Using our optimized protocols, we perform 3-5 rounds of panning. We adjust parameters like wash stringency and antigen concentration each round to drive the selection of high-affinity binders. Progress is monitored with polyclonal phage ELISA.

Step 4: High-Throughput Screening & Sequencing

Hundreds of individual clones are screened using automated monoclonal phage ELISA. All positive clones are sequenced, and advanced bioinformatics clusters the sequences into families, identifying unique lead candidates.

Step 5: Soluble Expression & Validation

• Lead scFv genes are subcloned for soluble expression in E. coli. Purified proteins undergo primary characterization.

• Binding Confirmation (ELISA/Flow Cytometry)

• Affinity Measurement (Octet BLI - Biolayer Interferometry)

• Specificity Profiling

Step 6: Delivery & Reporting

You receive a complete data package including all sequences, alignment files, characterization data, and physical deliverables (expression plasmids, purified proteins).

 Our Service Process Flowchart: 

☞Applications of the scFv Phage Display Platform

The versatility of our scFv platform enables breakthroughs across multiple sectors:

• Therapeutic Antibody Discovery: Rapid generation of fully human scFv leads against novel drug targets for oncology, immunology, and infectious diseases. The small size facilitates engineering into bispecifics, antibody-drug conjugates (ADCs), and other novel formats.

• CAR-T Cell Therapy: scFvs are the standard antigen-binding domain in Chimeric Antigen Receptors. Our platform is extensively used to discover and optimize scFvs for next-generation CAR-T therapies against solid and hematological tumors.

• In Vivo Diagnostics & Imaging: Development of scFv-based probes for PET, SPECT, and fluorescence imaging. Their rapid blood clearance and good tissue penetration enable high-contrast imaging.

• Research Reagents & Intrabodies: Production of highly specific scFvs for use in Western blot, IP, IHC, and as intracellular antibodies ("intrabodies") to modulate protein function within living cells.

• Affinity Maturation: Systematic improvement of existing antibody affinity by creating and screening focused mutagenesis libraries of the parent scFv.

• Epitope Mapping & Binning: Characterizing antigen binding sites using scFv panels to understand competition and epitope diversity, crucial for IP strategy and mechanistic studies.

• Biosensor & Diagnostic Development: Selection of stable, specific scFvs for integration into point-of-care diagnostic devices and biosensors.

Partner with Nebulabio’s expert team to leverage a proven, Nobel Prize-winning technology. Our integrated scFv Phage Display Platform provides a streamlined, reliable path from target to validated lead, accelerating your research and development timelines.